Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Inhibikase Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Written Notice, from the Listing Qualifications Department of The Nasdaq Stock Market LLC",
"Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements"
06/29/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc",
"Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2023 ARS Form ARS - Annual Report to Security Holders:
05/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/05/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/04/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/31/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Investor presentation
Docs: "Presentation of Inhibikase Therapeutics, Inc"
03/13/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/24/2023 SC 13D FiveT Investment Management Ltd reports a 4.8% stake in INHIBIKASE THERAPEUTICS INC
02/08/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/07/2023 D Form D - Notice of Exempt Offering of Securities:
01/31/2023 SC 13D FiveT Investment Management Ltd reports a 4.1% stake in INHIBIKASE THERAPEUTICS INC
01/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/26/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Form of Private Common Warrant",
"Form of PIPE Pre-Funded Warrant",
"Form of PIPE Common Warrant",
"Form of Placement Agent Warrant",
"Opinion of McDermott Will & Emery LLP",
"Securities Purchase Agreement, (Registered Direct)",
"Securities Purchase Agreement, (PIPE)",
"Registration Rights Agreement, (PIPE)",
"Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease , Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into definitive agreements for the issuance and sale of 6,744,187 of its shares of common stock at a purchase price of $0.86 per share in a registered direct offering. In a concurrent private placement, Inhibikase has also agreed to issue and sell 4,883,721 of its shares of common stock , at the same purchase price as i..."
01/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease",
"Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders"
01/24/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/17/2022 8-K Quarterly results
Docs: "Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs"
09/16/2022 8-K Investor presentation
Docs: "Conference Presentation of Inhibikase Therapeutics, Inc"
09/01/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/22/2022 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy